• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Mass administration of ivermectin may decrease prevalence of scabies and impetigo

byShayna BejaimalandShaidah Deghan, MSc. MD
December 10, 2015
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. Mass administration of ivermectin decreased the prevalence of scabies and impetigo in Fiji over the course of a year.

2. Mild adverse events were more frequent in the ivermectin group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Scabies, the skin condition caused by Sarcoptes scabiei var. hominis, is a public health concern in developing countries such as Fiji. This is because infestation is associated with stigma and impetigo, which can lead to complications systemically. Given that reinfestation may be common in countries where scabies is endemic, it would be timely to determine if mass drug administration may be helpful in decreasing prevalence of this disease. This study conducted a trial of mass drug administration for scabies control in Fiji to determine its impact on the prevalence of scabies and impetigo over a year.

There was a significant decrease in scabies prevalence in the standard care, permethrin and ivermectin groups. However, the greatest reduction was seen in the ivermectin group with a relative reduction rate of 94%. The prevalence of impetigo also declined in all study groups, with the greatest relative reduction of 67% in the ivermectin group. Mild adverse events were reported and occurred most frequently in the ivermectin group. Strengths of this study include trialing a novel means to help reduce scabies infestation. Limitations include not undergoing a true cluster-randomized controlled trial where multiple communities would be assigned to each treatment group.

Click to read the study, published today in NEJM

RELATED REPORTS

Early ivermectin treatment does not lower Covid-19 related hospitalizations

Screening program aids in safe ivermectin distribution in Loa loa endemic areas

2 Minute Medicine Rewind December 14, 2015

Relevant Reading: Impaired quality of life in adults and children with scabies from an impoverished community in Brazil

In-Depth [randomized controlled trial]: This trial randomly assigned three island communities in Fiji to three treatment regimens. These included standard care whereby infected individuals and their contacts were given permethrin, mass administration of permethrin or mass administration of ivermectin. These three communities were chosen for their relative isolation and population size to provide study power. Each community had one nurse-staffed clinic. The primary outcome of interest was change in the prevalence of scabies or impetigo over 12 months.

A total of 2051 people, over 85% of the population of the three communities, participated in the study. The prevalence of scabies reduced significantly in all three treatment groups as compared to baseline. In the standard care group there was a decrease from 36.6% to 18.8% (relative reduction in prevalence 49%; 95% [CI] 37-60), the permethrin group had a decrease from 41.7% to 15.8% (relative reduction 62%; 95% [CI] 49 to 75) and from 32.1% to 1.9% in the ivermectin group (relative reduction 94%; 95% CI 83 to 100). It is thought that the reason for a reduction in the standard care group was increased access to care during this study period. Impetigo prevalence rates also decreased across all treatment groups, with relative reductions of 32%, 54% and 67% for the standard care, permethrin and ivermectin groups respectively. Common adverse events were itching and headache and they were more common in the ivermectin group than the permethrin.

Image: PD/CDC

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ivermectinScabies
Previous Post

Venetoclax demonstrates antitumor activity in relapsed CLL

Next Post

Pre-operative magnetic resonance imaging may not improve contralateral breast cancer detection

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Early ivermectin treatment does not lower Covid-19 related hospitalizations

May 13, 2022
Screening program aids in safe ivermectin distribution in Loa loa endemic areas
Emergency

Screening program aids in safe ivermectin distribution in Loa loa endemic areas

November 29, 2017
2 Minute Medicine Rewind December 14, 2015
Chronic Disease

2 Minute Medicine Rewind December 14, 2015

December 15, 2015
Health A to Z

Patient Basics: Scabies

November 30, 2014
Next Post
Pre-operative magnetic resonance imaging may not improve contralateral breast cancer detection

Pre-operative magnetic resonance imaging may not improve contralateral breast cancer detection

Increased risk of stillbirth recurrence after a previous stillbirth

Gains in life expectancy linked with gains in health expectancy in old age

Time from symptom onset may not predict infarct volume in stroke

Curriculum for patient-centered counseling not linked to reduced low-value testing

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.